logo-loader
viewAmati Global Investors

Amati Global Investors CEO sees good times ahead for UK biotechs as coronavirus fight steps up

Paul Jourdan, Amati Global Investors' chief executive, believes the UK might see a real biotech investment boom from work undertaken to tackle the coronavirus outbreak.

Amati runs two funds, a general fund for companies below FTSE 100 level and an AIM-focused VCT (LON:AMAT).

The disciplines of running a VCT have taught the fund the virtue of being long term investors in businesses, he says, and in the biotech arena that is paying off as some of its investments are at the forefront of the coronavirus fight.

Oxford Biomedica is providing manufacturing support to the Oxford Jenner Initiative to find a vaccine, for example.

Synairgen (LON:SNG) is working on a treatment to alleviate the symptoms of severe coronavirus sufferers, while Fusion Antibodies has started a research project using its humanised antibodies to find a treatment.

“The risks of being out of the market currently are as great as being in it,” he says.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tabula launches new ETF focussing on North American High Yield Credit Market

Tabula Investment Management Limited (LSE: TABS) CEO MJ Lytle joined Steve Darling from Proactive with news the company has started a new ETF that will be exclusively located on the London Stock Exchange under the ticker “TABS”  Lytle telling Proactive that ETF will focus on short exposure...

8 hours, 11 minutes ago

2 min read